Tuberculosis (TB) is a contagious illness resulting from the presence of the bacterium Mycobacterium tuberculosis. While its primary impact is on the lungs, tuberculosis (TB) can also affect various other parts of the body. TB is communicable and spreads through the air when an infected person coughs or sneezes, making it a significant public health concern. Symptoms of TB include persistent cough, chest pain, weight loss, and fatigue. The disease can be latent, where individuals have TB bacteria in their bodies but do not exhibit symptoms, or active, leading to the manifestation of symptoms and the potential for transmission to others. TB is preventable and treatable. Prevention involves vaccination, known as the Bacillus Calmette-Guérin (BCG) vaccine, and avoiding close contact with individuals who have active TB. Treatment typically requires a course of antibiotics, and it is crucial for individuals to complete the full treatment regimen to ensure recovery and minimize the risk of drug-resistant strains. Public health efforts focus on early detection through testing, contact tracing, and the prompt initiation of treatment. TB disproportionately affects vulnerable populations, and addressing social determinants of health, such as poverty and access to healthcare, is essential in controlling the spread of the disease. In summary, tuberculosis is a communicable disease with symptoms affecting the respiratory system. With proper prevention, early detection, and comprehensive treatment, the impact of TB on global public health can be significantly mitigated.
Speaker lineup for this track will be announced soon.
Browse all speakers →Introduction: Tuberculosis (TB) remains a significant global public health challenge. Although England is classified as a low-incidence country with 7.7 cases per 100,000 population, Wolverhampton…
Background: The incidence of Tuberculosis (TB) in Japan in 2023 was 8.1 cases per 100,000 persons. Patients with active TB require hospitalization in isolation with an average length of hospital stay…
Background : Effective TB diagnosis is crucial for timely management and favorable treatment outcomes. In 2022, Uganda reported achieving 100% TB case detection but only 63% of notified cases were…
Sessions are CPD-accredited; certificates issued to every registered delegate within two weeks of the conference.
Oral and poster slots for original Tuberculosis work, reviewed by the scientific committee.
Meet public health researchers, educators, and policy leaders from around the world across three days.
Accepted abstracts appear in the indexed conference proceedings with a citable DOI.
Plenary lectures from leading voices shaping Tuberculosis research and practice.
Attend in person in Singapore or join virtually — same programme, same certificate.
Oral and poster slots for your work — in person in Singapore or online. Not presenting? Attend as a delegate to learn from the field.
The Tuberculosis track is a dedicated stream within IPHC 2027 covering the latest research, innovation, and best practice in Tuberculosis. It brings together researchers, educators, and practitioners for oral presentations, posters, and discussion.
Public health researchers, practitioners, epidemiologists, educators, doctoral students, and policy leaders with an interest in Tuberculosis are all welcome — whether presenting or attending.
Yes. Submit an abstract for oral or poster presentation. All submissions are peer-reviewed by the scientific committee; accepted abstracts appear in the indexed proceedings.
Yes. IPHC 2027 is a hybrid conference — attend the Tuberculosis track in person in Singapore or join live online, with on-demand access afterward.
Singapore · March 15–17, 2027· Hybrid · in-person & virtual
Attend without presenting.
